Close Menu

NEW YORK – Biomedical software company BostonGene said on Tuesday that it is collaborating with the Dana-Farber Cancer Institute's Weinstock Laboratory to research treatment response and resistance among patients with T-cell lymphomas.

Specifically, the partnership will focus on uncovering mechanisms that might cause patients' response or resistance to PI3 kinase inhibitors, including duvelisib (Verastem Oncology's Copiktra). Causes of adverse effects of duvelisib in patients with T-cell lymphomas will also be part of the collaboration.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by

Recent advances in single-cell technologies have provided unprecedented -omic-level insights into cellular heterogeneity and function. 

Sponsored by

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Sponsored by
Akoya Biosciences

Single-cell omics assays have become essential tools for identifying and characterizing cell types and states of complex tissues. While each single-modality assay reveals distinctive features about the sequenced cells, true multiomics assays are still in the early stage of development. 

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.